EUVIMEDEUVIMED entdecken
Crossref

MDMA Therapy for PTSD: Inching Closer to—or Farther From—Approval?

Leigh Davitian

The Senior Care Pharmacist · 2024

DOI: 10.4140/tcp.n.2024.311 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Senior Care Pharmacist, 2024. Verfasst von Leigh Davitian. Beteiligte Einrichtung: Dumbarton Group & Associates Health Care Law and Policy Firm The Foundry Building 1050 30th Street, NW Washington, DC 20007 Phone: 202-674-7747. Hauptthemen laut MEDLINE: Stress Disorders, Post-Traumatic, N-Methyl-3,4-methylenedioxyamphetamine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In recent years, scientists have initiated a renaissance in psychedelic research following decades of prohibition. Compounds such as ketamine, LSD, and psilocybin 'once primarily associated with recreational use' are now being investigated for their therapeutic potential, with promising results. An estimated 40-60% of people with post-traumatic stress disorder (PTSD) do not respond to selective serotonin reuptake inhibitors, which are the first-line medications for this condition. However, one standout among these psychedelics is methylenedioxy methamphetamine (MDMA), which has demonstrated exceptional efficacy in treating PTSD and medication-resistant depression. Growing results in research were so positive that, in 2017, the US Food and Drug Administration (FDA) designated MDMA-assisted psychotherapy as a breakthrough therapy. Though MDMA is not yet officially legal or approved for clinical use, Phase 3 trials are underway, and expanded access status was granted in 2020 in the United States and Israel. Preliminary clinical studies are extremely promising, and the FDA could approve MDMA-assisted psychotherapy for PTSD as early as 2024, offering a potential treatment for this crippling mental health condition that affects almost 3.5% of US adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stress Disorders, Post-TraumaticN-Methyl-3,4-methylenedioxyamphetamineHumansHallucinogensDrug Approval

Substanzen

N-Methyl-3,4-methylenedioxyamphetamineHallucinogens

Autor:innen und Institutionen

  • Dumbarton Group & Associates Health Care Law and Policy Firm The Foundry Building 1050 30th Street, NW Washington, DC 20007 Phone: 202-674-7747.

Zitieren

APA

Davitian, L. (2024). MDMA Therapy for PTSD: Inching Closer to—or Farther From—Approval?. The Senior Care Pharmacist. https://doi.org/10.4140/tcp.n.2024.311

Vancouver

Davitian L. MDMA Therapy for PTSD: Inching Closer to—or Farther From—Approval?. The Senior Care Pharmacist. 2024. doi:10.4140/tcp.n.2024.311

BibTeX
@article{Davitian2024,
  author = {Davitian, Leigh},
  title = {MDMA Therapy for PTSD: Inching Closer to—or Farther From—Approval?},
  journal = {The Senior Care Pharmacist},
  year = {2024},
  doi = {10.4140/tcp.n.2024.311}
}
Kostenlos starten →